1.Sales and profit
See section β- Minerva Neurosciences, Inc. lost $293M in fiscal 2025.
Minerva Neurosciences, Inc.
NERV Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Last close Β· Oct 23, 2026
$2.30
4.2%KIRAβs summary AI analyst
Hi! I read Minerva Neurosciences, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
1 to watch
2.Cash and shareholders
See section β- No open-market insider trades in the last 12 months.
Minerva Neurosciences, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$293M
No. It lost money last year.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$182M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$36.74 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY16
Revenue β
FY17
Revenue $0.0M
FY18
Revenue $0.0M
FY19
Revenue $0.0M
FY20
Revenue $41.2M
FY21
Revenue $0.0M
FY22
Revenue $0.0M
FY23
Revenue $0.0M
FY24
Revenue $0.0M
FY25
Revenue β
Margins, % of revenue
FY16
Gross β
Operating β
Net β
FCF β
FY17
Gross β
Operating β
Net β
FCF β
FY18
Gross β
Operating β
Net β
FCF β
FY19
Gross β
Operating β
Net β
FCF β
FY20
Gross β
Operating 4.5%
Net 4.7%
FCF β
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Minerva Neurosciences, Inc. lost $293M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY16
Net income β$31.0M
FY17
Net income β$31.5M
FY18
Net income β$50.2M
FY19
Net income β$72.2M
FY20
Net income $1.9M
FY21
Net income β$49.9M
FY22
Net income β$32.1M
FY23
Net income β$30.0M
FY24
Net income $1.4M
FY25
Net income β$293M
Net income
Q3 '23
Net income β$7.8M
Q4 '23
Net income β$9.0M
Q1 '24
Net income β$8.6M
Q2 '24
Net income β$8.2M
Q3 '24
Net income $22.5M
Q4 '24
Net income β$4.3M
Q1 '25
Net income β$3.8M
Q2 '25
Net income β$3.3M
Q3 '25
Net income β$2.7M
Q4 '25
Net income β$284M
Q1 '26
Net income β$125M
Q2 '26
Net income $17.5M
Diluted EPS
FY16
Diluted EPS β$0.99
FY17
Diluted EPS β$0.83
FY18
Diluted EPS β$1.29
FY19
Diluted EPS β$1.85
FY20
Diluted EPS $0.05
FY21
Diluted EPS β$9.35
FY22
Diluted EPS β$6.01
FY23
Diluted EPS β$4.61
FY24
Diluted EPS $0.19
FY25
Diluted EPS β$34.67
Diluted EPS
Q3 '23
Diluted EPS β$1.03
Q4 '23
Diluted EPS β$1.15
Q1 '24
Diluted EPS β$1.13
Q2 '24
Diluted EPS β$1.09
Q3 '24
Diluted EPS $2.97
Q4 '24
Diluted EPS β$0.56
Q1 '25
Diluted EPS β$0.50
Q2 '25
Diluted EPS β$0.43
Q3 '25
Diluted EPS β$0.36
Q4 '25
Diluted EPS β$33.38
Q1 '26
Diluted EPS β$2.86
Q2 '26
Diluted EPS β$0.14
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY16
Free cash flow β
FY17
Free cash flow $3.0M
FY18
Free cash flow β
FY19
Free cash flow β
FY20
Free cash flow β
FY21
Free cash flow β
FY22
Free cash flow β$24.7M
FY23
Free cash flow β
FY24
Free cash flow β
FY25
Free cash flow β
Cash from operations vs capital spending
FY16
Cash from operations β$25.7M
Capital spending β
FY17
Cash from operations $3.1M
Capital spending $0.1M
FY18
Cash from operations β$41.9M
Capital spending β
FY19
Cash from operations β$43.4M
Capital spending β
FY20
Cash from operations β$33.8M
Capital spending β
FY21
Cash from operations β$24.6M
Capital spending β
FY22
Cash from operations β$24.6M
Capital spending $0.0M
FY23
Cash from operations β$14.8M
Capital spending β
FY24
Cash from operations β$19.6M
Capital spending β
FY25
Cash from operations β$13.5M
Capital spending β
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$4.8M
Capital spending β
Q4 '23
Cash from operations β$6.0M
Capital spending β
Q1 '24
Cash from operations β$6.1M
Capital spending β
Q2 '24
Cash from operations β$3.9M
Capital spending β
Q3 '24
Cash from operations β$4.4M
Capital spending β
Q4 '24
Cash from operations β$5.2M
Capital spending β
Q1 '25
Cash from operations β$4.1M
Capital spending β
Q2 '25
Cash from operations β$2.0M
Capital spending β
Q3 '25
Cash from operations β$2.9M
Capital spending β
Q4 '25
Cash from operations β$4.5M
Capital spending β
Q1 '26
Cash from operations β$5.4M
Capital spending β
Q2 '26
Cash from operations β$13.3M
Capital spending β
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY16
Dividends β
Buybacks β
FY17
Dividends β
Buybacks $0.0M
FY18
Dividends β
Buybacks β
FY19
Dividends β
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY16
Diluted shares 0.03B
FY17
Diluted shares 0.04B
FY18
Diluted shares 0.04B
FY19
Diluted shares 0.04B
FY20
Diluted shares 0.04B
FY21
Diluted shares 0.01B
FY22
Diluted shares 0.01B
FY23
Diluted shares 0.01B
FY24
Diluted shares 0.01B
FY25
Diluted shares 0.01B
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Minerva Neurosciences, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY16
Cash $83.0M
Debt β
FY17
Cash $128M
Debt β
FY18
Cash $88.0M
Debt β
FY19
Cash $45.9M
Debt β
FY20
Cash $25.4M
Debt β
FY21
Cash $60.8M
Debt β
FY22
Cash $36.1M
Debt β
FY23
Cash $40.9M
Debt β
FY24
Cash $21.4M
Debt β
FY25
Cash $82.3M
Debt β
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $60.8M | $36.1M | $40.9M | $21.4M | $82.3M |
| Current ratio | 22.1x | 29.2x | 12.6x | 7.9x | 36.3x |
| Quick ratio | 22.1x | 29.2x | 12.6x | 7.9x | 36.3x |
| Total assets | $77.1M | $55.1M | $56.9M | $37.1M | $98.0M |
| Total liabilities | $69.1M | $75.1M | $85.4M | $62.8M | $234M |
| Shareholders' equity | $8.0M | β$20.0M | β$28.5M | β$25.7M | β$141M |
| Net debt (β = net cash) | β | β | β | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY16
Return on capital β
Return on equity β29.3%
Return on assets β23.4%
FY17
Return on capital β
Return on equity β26.5%
Return on assets β19.9%
FY18
Return on capital β
Return on equity β45.2%
Return on assets β31.1%
FY19
Return on capital β
Return on equity β122.3%
Return on assets β66.6%
FY20
Return on capital β
Return on equity 4.8%
Return on assets 2.9%
FY21
Return on capital β
Return on equity β164.6%
Return on assets β74.1%
FY22
Return on capital β
Return on equity β
Return on assets β48.6%
FY23
Return on capital β
Return on equity β
Return on assets β53.6%
FY24
Return on capital β
Return on equity β
Return on assets 3.1%
FY25
Return on capital β
Return on equity β
Return on assets β434.3%
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | 2 / 7 | 1 / 7 | 4 / 7 | 3 / 7 | 4 / 7 | 2 / 7 | 2 / 7 | β / 6 |
| Accruals ratio | β4.0% | β21.9% | β5.1% | β26.5% | 52.9% | β37.6% | β11.3% | β27.2% | 44.6% | β414.3% |
| Altman Z'' | 3.00 | 2.61 | β1.51 | β14.62 | β1.99 | β12.93 | β20.45 | β21.36 | β35.65 | β19.18 |
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | $0.0M | $0.0M | $0.0M | $41.2M | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Research and development | $20.4M | $30.3M | $34.9M | $58.1M | $22.0M | $32.0M | $14.6M | $12.7M | $11.9M | $5.8M |
| Operating income | β$30.2M | β$41.2M | β$51.7M | β$75.9M | $1.8M | β$45.4M | β$25.2M | β$23.1M | β$21.8M | β$15.1M |
| Pretax income | β$31.0M | β$40.9M | β$50.2M | β$74.4M | $1.9M | β$51.7M | β$32.1M | β | β | β |
| Income tax | $0.0M | β$9.4M | $0.0M | β$2.3M | β | β$1.8M | β | β | β | β |
| Net income | β$31.0M | β$31.5M | β$50.2M | β$72.2M | $1.9M | β$49.9M | β$32.1M | β$30.0M | $1.4M | β$293M |
| Diluted EPS | β$0.99 | β$0.83 | β$1.29 | β$1.85 | $0.05 | β$9.35 | β$6.01 | β$4.61 | $0.19 | β$34.67 |
| Diluted shares | 0.03B | 0.04B | 0.04B | 0.04B | 0.04B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$25.7M | $3.1M | β$41.9M | β$43.4M | β$33.8M | β$24.6M | β$24.6M | β$14.8M | β$19.6M | β$13.5M |
| Capital expenditure | β | $0.1M | β | β | β | β | $0.0M | β | β | β |
| Free cash flow | β | $3.0M | β | β | β | β | β$24.7M | β | β | β |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | $0.0M | $0.0M | $0.0M |
| Stock-based compensation | $3.6M | $5.0M | $8.2M | $9.2M | $9.7M | $5.2M | $4.1M | $2.0M | $1.3M | $1.3M |
| Share buybacks | β | $0.0M | β | β | β | β | β | β | β | β |
| Dividends and buybacks | β | $0.0M | β | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $83.0M | $128M | $88.0M | $45.9M | $25.4M | $60.8M | $36.1M | $40.9M | $21.4M | $82.3M |
| Current assets | $83.9M | $130M | $90.0M | $47.1M | $27.4M | $62.2M | $40.2M | $42.0M | $22.3M | $83.1M |
| Current liabilities | $9.7M | $6.8M | $3.6M | $6.6M | $3.2M | $2.8M | $1.4M | $3.3M | $2.8M | $2.3M |
| Property and equipment, net | $0.0M | $0.1M | $0.0M | $0.0M | β | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Goodwill | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M | $14.9M |
| Intangible assets | $34.2M | $34.2M | $34.2M | $15.2M | $15.2M | β | β | β | β | β |
| Total assets | $133M | $184M | $139M | $77.5M | $57.6M | $77.1M | $55.1M | $56.9M | $37.1M | $98.0M |
| Total liabilities | $27.0M | $52.1M | $48.9M | $49.7M | $5.0M | $69.1M | $75.1M | $85.4M | $62.8M | $234M |
| Shareholders' equity | $106M | $132M | $90.3M | $27.8M | $52.7M | $8.0M | β$20.0M | β$28.5M | β$25.7M | β$141M |
| Margins | ||||||||||
| Operating margin | β | β | β | β | 4.5% | β | β | β | β | β |
| EBITDA margin | β | β | β | β | 4.5% | β | β | β | β | β |
| Net margin | β | β | β | β | 4.7% | β | β | β | β | β |
| Returns | ||||||||||
| Return on capital employed | β24.5% | β23.3% | β38.2% | β107.0% | 3.4% | β61.1% | β47.0% | β43.2% | β63.7% | β15.8% |
| Return on equity | β29.3% | β26.5% | β45.2% | β122.3% | 4.8% | β164.6% | β | β | β | β |
| Return on assets | β23.4% | β19.9% | β31.1% | β66.6% | 2.9% | β74.1% | β48.6% | β53.6% | 3.1% | β434.3% |
| Return on tangible equity | β54.5% | β38.2% | β121.8% | β | 8.6% | β | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | β100.0% | β | β | β | β |
| Net income growth | β | β | β | β | β | β2,671.4% | β | β | β | β20,492.2% |
| EPS growth | β | β | β | β | β | β18,800.0% | β | β | β | β18,347.4% |
| Share count change | β | 20.4% | 2.3% | 0.6% | 4.9% | β86.9% | 0.0% | 21.8% | 16.4% | 11.7% |
| Financial health | ||||||||||
| Current ratio | 8.7x | 18.9x | 24.9x | 7.1x | 8.7x | 22.1x | 29.2x | 12.6x | 7.9x | 36.3x |
| Quick ratio | 8.7x | 18.9x | 24.9x | 7.1x | 8.7x | 22.1x | 29.2x | 12.6x | 7.9x | 36.3x |
| Capital allocation | ||||||||||
| Stock comp / revenue | β | β | β | β | 23.6% | β | β | β | β | β |
| Payouts / FCF | β | 0.0% | β | β | β | β | β | β | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 2.0 | 1.0 | 4.0 | 3.0 | 4.0 | 2.0 | 2.0 | β |
| Altman Z'' | 3.0 | 2.6 | β1.5 | β14.6 | β2.0 | β12.9 | β20.4 | β21.4 | β35.7 | β19.2 |
| Accruals ratio | β4.0% | β21.9% | β5.1% | β26.5% | 52.9% | β37.6% | β11.3% | β27.2% | 44.6% | β414.3% |
Source: SEC EDGAR XBRL filings (CIK 0001598646). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.